Our study was the first clinical study conducted on lurbinectedin in Chinese patients, as well as the first dose-expansion study with an FDA-approved dosage (3.2 mg/m2, 1 h IV q3wk, without G-CSF primary prophylaxis) in Asian SCLC patients as second-line therapy. The gene discussed is CSF3; the disease is small cell lung carcinoma.